Enanta Pharmaceuticals (ENTA) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We will require substantial additional funding to achieve our goals. A failure to obtain this funding when needed could force us to delay, limit, reduce or terminate some or all of our product development efforts
2. 02potential fluctuations in foreign currency exchange rates
3. 03regimen at or above current levels of sales, our royalty revenues, as well as our retained cash portion of royalties, will be adversely affected
4. 04RSV, CSU and AD, as well as COVID-19 and HBV, represent competitive therapeutic areas
5. 05over 60 years of age (Pfizer/ABRYSVO® and Moderna/Mresvia®) and one approved RSV vaccine for adults over 50 years of age (GSK/AREXVY®)
6. 06We have not developed independently any approved products and we have limited clinical development experience, which makes it difficult to assess our ability to develop and commercialize our product candidates
7. 07If we are not successful in developing zelicapavir or EDP-323, or discovering and developing KIT and STAT6 inhibitors, or in obtaining a partner to advance EDP-235 or EDP-514, or in discovering further product candidates, our ability to expand our business and achieve our strategic objectives will be impaired
8. 08a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all
9. 09If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates
10. 10We may encounter difficulties expanding our operations successfully to advance our product candidates

Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates

1. 11varying interpretations of data by the FDA, the EMA and similar foreign regulatory agencies
2. 12Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any product we may develop
3. 13Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials
4. 14The regulatory approval processes of the FDA, the EMA and other comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain timely regulatory approval for our product candidates, our business will be substantially harmed
5. 15the approval policies or regulations of the FDA, the EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
6. 16The regulatory pathway for approval of a therapeutic treatment for COVID-19 such as EDP-235 is continually evolving and may result in unexpected or unforeseen challenges and longer timelines than seen for earlier COVID-19 vaccines and therapeutics
7. 17injunctions or the imposition of civil or criminal penalties
8. 18We may delay or terminate the development of a product candidate at any time if we believe the perceived market or commercial opportunity does not justify further investment, which could materially harm our business and adversely affect our stock price

Risks Related to Commercialization of Our Product Candidates

1. 19Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives in the United States could harm our business
2. 20Foreign governments tend to impose strict price controls, which may adversely affect our future profitability
3. 21If, in the future, we are unable to establish our own sales, marketing and distribution capabilities or enter into licensing or collaboration agreements for these purposes, we may not be successful in commercializing any product candidates
4. 22unforeseen costs and expenses associated with creating an independent sales and marketing organization
5. 23Commercial success of our product candidates depends upon significant market acceptance among physicians, patients and healthcare payors of any resulting approved drug
6. 24the effectiveness of our sales and marketing efforts

Risks Related to Our Dependence on Third Parties

1. 25We may not be successful in establishing new product collaborations, which could adversely affect our ability to develop and commercialize one or more of our product candidates. If we are unsuccessful in maintaining or forming alliances on favorable terms, our business may not succeed
2. 26the competitiveness of any product candidate that is commercialized could be reduced
3. 27including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates
4. 28To the extent we elect to enter into additional licensing or collaboration agreements to partner our product candidates, our dependence on such relationships may adversely affect our business

Risks Related to Our Intellectual Property Rights

1. 29We are competing to develop intellectual property in areas of small-molecule drug development that are highly competitive. We could be unsuccessful in obtaining or maintaining adequate patent protection for one or more of our product candidates
2. 30Claims that our product candidates or the sale or use of our products infringe the patent or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided
3. 31Issued patents covering one or more of our product candidates could be found invalid or unenforceable if challenged in court, including as a result of counterclaims filed against us in connection with our efforts to enforce our intellectual property rights against third parties
4. 32Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline
5. 33Intellectual property rights do not necessarily protect us from all potential threats to our competitive advantage
6. 34Unfavorable outcomes in intellectual property litigation could limit our research and development activities and/or our ability to commercialize certain products
7. 35clinical trials, continue our internal research programs, in-license needed technology, or enter into strategic partnerships that would help us bring our product candidates to market
8. 36Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information
9. 37Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our products

Risks Related to Our Industry

1. 38If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
2. 39a decline in our stock price
3. 40Our internal computer systems, or those of our collaborator, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs for our product candidates
4. 41information, we could incur substantial liability, our reputation would be damaged, and the further development of our product candidates could be delayed
5. 42analogous anti-kickback, fraud and abuse and healthcare laws and regulations states, as well as in foreign countries

Risks Related to Our Common Stock

1. 43Our stock price has been, and is likely to continue to be, volatile, and thus our stockholders could incur substantial losses
2. 44A sale of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
3. 45If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research about our business, our stock price and trading volume would likely decline
4. 46Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which they might otherwise receive a premium for their shares
5. 47require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws
6. 48Our employment agreements with our executive officers may require us to pay severance benefits to any of those persons who are terminated in connection with a change of control of us, which could harm our financial condition or results
7. 49Because we do not anticipate paying cash dividends on our common stock for the foreseeable future, investors in our common stock may never receive a return on their investment
8. 50Our ability to use future net operating loss carryforwards, research and development tax credit carryforwards, and certain other tax attributes may be limited
9. 51We are a smaller reporting company, and any decision on our part to comply only with reduced reporting and disclosure requirements applicable to such companies could make our common stock less attractive to investors
10. 52If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
11. 53Our insurance policies are expensive and only protect us from specified business risks, which will leave us exposed to significant uninsured liabilities
12. 54Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches, which could adversely affect our business
13. 55Use of social media could give rise to liability or reputational harm
14. 56We maintain our cash at financial institutions, often in balances that exceed federally insured limits